1. Executive Summary
Bioneer offers a
comprehensive and scientifically validated platform centered around the fission
yeast, Schizosaccharomyces pombe, a powerful model organism for
eukaryotic cell biology and drug discovery. Central to this platform is a
genome-wide deletion mutant library, available in both heterozygous diploid and
haploid formats, covering approximately 98.5% of the S. pombe genome. This library was meticulously constructed via
homologous recombination, incorporating unique molecular barcodes for each
mutant, based on methodologies published in high-impact peer-reviewed
literature and developed through a major international collaboration involving
Bioneer, KRIBB, and Cancer Research UK. The heterozygous library enables the GPScreen™-FAST service, a high-throughput functional
genomics screen for drug target identification based on the principle of
drug-induced haploinsufficiency (DIH). This service involves determining a
compound's GI50, screening the pooled heterozygous library, and using Next
Generation Sequencing (NGS) to quantify barcode abundance, thereby identifying
gene deletions conferring sensitivity to the compound. Rigorous quality control
was implemented during library construction, and validation tools are available
for users. Individual deletion strains (heterozygous or haploid) can be
ordered, requiring lookup via the external PomBase database and execution of a Material Transfer
Agreement (MTA). While Bioneer possesses general gene synthesis and editing
capabilities, dedicated services for generating custom S. pombe mutants beyond the existing deletion collection are not
explicitly advertised, necessitating direct inquiry for such needs. This report
details the technical specifications, methodologies, applications, and access
procedures for Bioneer's S. pombe resources, providing researchers with the information
needed to evaluate their suitability for functional genomics and drug discovery
applications.
2. Introduction
2.1. Schizosaccharomyces pombe as a Model Organism
The fission
yeast, Schizosaccharomyces pombe, serves as a highly valuable
model organism for investigating fundamental aspects of eukaryotic cell
biology, functional genomics, and drug discovery mechanisms. Its utility stems
from several key characteristics: genetic tractability, a relatively rapid cell
cycle facilitating molecular analysis, and conserved cellular processes that
exhibit significant homology with those in mammalian cells, including humans.
Notably, S. pombe shares homology
with numerous human genes, including those implicated in cancer, making it
particularly relevant for biomedical research. Compared to the budding yeast Saccharomyces cerevisiae, S. pombe often displays greater
similarity to mammalian systems in pathways such as cell cycle control and
checkpoint regulation. This resemblance has led to its designation as a
"micro-mammal" by the National Institutes of Health (NIH) model
organism grouping, underscoring its relevance for studying complex eukaryotic
processes.
2.2. Overview of Bioneer's S. pombe Resources
Bioneer has
established a significant research platform leveraging the advantages of S. pombe. The cornerstone of this
platform is a comprehensive genome-wide deletion mutant library, meticulously
constructed and validated. This resource is available in two primary formats: a
heterozygous diploid library, containing mutants with one deleted gene copy,
and a haploid library, containing mutants with a single deleted gene copy (for
non-essential genes).
Capitalizing on
the heterozygous library, Bioneer offers the GPScreen™-FAST
service, a functional genomics screening platform primarily designed for
identifying potential drug targets. This service employs the principle of
drug-induced haploinsufficiency (DIH), where the sensitivity of heterozygous
mutants to a compound can reveal genes involved in the drug's mechanism of
action.
Beyond the
screening service, researchers can procure individual mutant strains directly
from the library collection for focused studies. The development of this
extensive resource was not undertaken in isolation but resulted from a
significant international collaboration involving Bioneer, the Korea Research
Institute of Bioscience and Biotechnology (KRIBB), and Cancer Research UK
(CRUK), including the laboratory of Dr. Paul Nurse. This collaborative origin
underscores the scientific rigor invested in the library's creation.
3. The Bioneer S.
pombe Genome-wide Deletion Mutant Library
3.1. Library Construction and Scientific Foundation (Kim et
al., 2010)
The scientific
foundation and construction methodology for Bioneer's S. pombe
heterozygous diploid deletion library are rigorously documented in a seminal
publication by Kim et al. in Nature Biotechnology (2010). This publication
provides the essential details regarding the library's creation and initial
characterization.
The parental
strain selected for constructing the heterozygous library was SP286, a diploid
strain with the genotype ade6-M210/ade6-M216,
leu1-32/leu1-32, ura4-D18/ura4-D18 h+/h+. The core strategy involved
targeted gene deletion via homologous recombination, a standard and precise
method for genetic manipulation in yeast. For each target gene, a deletion
cassette was generated. This cassette contained the KanMX4 selectable marker
gene, conferring resistance to the antibiotic G418 (Geneticin), enabling
selection of successful transformants. Crucially, the KanMX4 marker within each
cassette was flanked by unique DNA sequences: an upstream tag (UPTAG) and a
downstream tag (DNTAG), collectively referred to as molecular barcodes. These
barcodes serve as unique identifiers for each specific deletion mutant. The
cassette also included regions of homology (RHG) corresponding to the sequences
flanking the target gene's open reading frame (ORF) to direct the homologous
recombination event. Transformation of these cassettes into the parental SP286
strain was achieved using a standard lithium acetate method.
The design of the
unique UPTAG and DNTAG barcodes was a critical aspect of the library's
construction, enabling subsequent high-throughput applications. Barcode
sequences were computationally generated using BioPerl,
adhering to strict design criteria to ensure specificity and reliable
detection. These criteria included a target melting temperature (Tm) of 60°C,
minimal potential for cross-hybridization between different barcodes, avoidance
of secondary structure formation (checked using RNAfold
and mfold), and lack of significant similarity to
endogenous S. pombe genomic sequences
(verified using BLAST).
The publication
of the library's construction methodology in a high-impact, peer-reviewed
journal like Nature Biotechnology signifies a high level of scientific scrutiny
regarding the methods and initial validation data. Furthermore, the involvement
of leading research institutions and experts, such as KRIBB and Dr. Paul
Nurse's group at CRUK, lends considerable weight to the scientific validity and
reliability of this resource. This documented rigor provides a strong
foundation of confidence for researchers utilizing the library or services
derived from it, such as GPScreen™.
The incorporation
of unique UPTAG and DNTAG barcodes for every individual deletion mutant is a
key design feature with significant implications. These molecular identifiers
are precisely what enable the powerful, pooled screening strategies employed in
services like GPScreen™. In a pooled format, where
thousands of mutants are grown together, the barcodes allow for the
deconvolution of the population after experimental treatment. Using NGS, the
barcodes can be amplified and sequenced, providing a quantitative measure of
the relative abundance of each mutant strain within the pool. Without these
unique tags, such high-throughput quantitative analysis of pooled mutants would
not be feasible.
3.2. Library Specifications and Formats
Bioneer offers
the S. pombe deletion library in two
main formats, catering to different experimental needs:
● Heterozygous Diploid Library: This is the primary library described in the foundational Kim et al. (2010) paper and forms the basis of the GPScreen™ service. Each strain in this library carries one functional copy and one deleted copy of the target gene. This heterozygous state is essential for DIH studies. The library boasts comprehensive coverage, encompassing approximately 98.4% to 98.6% of the annotated S. pombe genome or ORFs. Sources report the total number of distinct heterozygous strains as 4,845. While minor variations in reported numbers exist across different Bioneer materials, the consistently high genome coverage is evident. This library includes deletions of both essential and non-essential genes, as essential genes can only be maintained in the heterozygous state.
● Haploid Deletion Mutant Set (Ver 6.0): A corresponding haploid deletion set is also available, derived from the heterozygous diploid library. This derivation process involves inducing meiosis in the diploid strains and selecting haploid spores that carry the gene deletion marker (KanMX4). Consequently, this set only contains deletions of non-essential genes, as haploid cells cannot survive the deletion of an essential gene. The haploid library (Version 6.0) reportedly targets approximately 98.5% of the genome, representing deletions in 3,497 non-essential genes. (Note: Some sources mention slightly different coverage or strain counts, potentially reflecting different versions or reporting conventions). The haploid strains utilize the KanMX4 selective marker and have defined genetic backgrounds (ED666: h+, ade6-M210 ura4-D18 leu1-32; ED668: h+, ade6-M216 ura4-D18 leu1-32).
The
key specifications for these library formats are summarized below:
Table 3.2.1: Bioneer S.
pombe Deletion Library Specifications
|
Feature |
Heterozygous Diploid Library |
Haploid Deletion Mutant Set (Ver 6.0) |
|
Library Type |
Heterozygous Diploid |
Haploid |
|
Parental/Background Strain Genotype |
SP286: ade6-M210/M216, leu1-32/32, ura4-D18/D18 h+/h+ |
ED666/ED668: h+, ade6-M210/M216 ura4-D18 leu1-32 |
|
Coverage (% Genome/ORFs) |
98.6% |
~98.5% (non-essential genes) |
|
Approx. Strain Count |
4,845 |
3,497 |
|
Selective Marker |
KanMX4 (G418 Resistance) |
KanMX4 (G418 Resistance) |
|
Gene Type Covered |
Essential & Non-essential |
Non-essential only |
|
Key Application |
GPScreen™ (DIH), Essential Gene Studies |
Loss-of-function studies |
|
Key Reference/Source |
Kim et al., 2010 |
Bioneer Product Info |
This table
facilitates a direct comparison, highlighting that the heterozygous library is
necessary for DIH screens like GPScreen™ and for
studying essential genes, while the haploid library is suited for direct
loss-of-function studies of non-essential genes.
3.3. Quality Control and Validation
Ensuring the
quality and accuracy of a genome-wide resource like this deletion library is
paramount. The initial construction phase, as documented by Kim et al. (2010),
incorporated multiple rigorous quality control (QC) steps:
1. Colony PCR: This was used routinely to confirm that the deletion cassette had integrated at the correct genomic locus, replacing the target gene.
2. Dideoxy Sequencing: PCR products spanning the integration junctions for each mutant were sequenced. This step served to confirm the unique UPTAG and DNTAG barcode sequences associated with each deletion and verified the precise boundaries of the deleted genomic region.
3. Southern Blot Analysis: To assess the frequency of unintended, off-target integration events (where the deletion cassette integrates elsewhere in the genome), Southern blot analysis was performed on a subset of strains using the KanMX4 marker as a probe. This analysis indicated a low frequency of such events, estimated at less than 1%.
4. Phenotypic Analysis (Essentiality Determination): Gene essentiality was assessed by sporulating the heterozygous diploid mutants and examining the viability of the resulting haploid spores via microscopy and colony formation assays. Tetrad analysis was used to further confirm essentiality for genes initially identified as such. Crucially, linkage analysis was performed by checking G418 sensitivity in viable spores; viability linked to G418 sensitivity confirmed the absence of the deletion (wild-type spore), while viability linked to G418 resistance confirmed the presence of the deletion (mutant spore).
In
addition to the QC performed during construction, Bioneer provides resources
for users to perform their own validation. AccuOligo® S. pombe Validation Primer Sets (e.g., Ver 3.0, containing 3,308
primers) are available. These primer sets are designed for colony PCR assays to
allow users to independently confirm the deletion of the target gene and the
correct insertion of the tagged KanMX cassette in the
specific mutant strains they receive or use. The validation typically involves
PCR reactions using gene-specific primers flanking the deletion site and common
primers annealing within the KanMX module.
This
multi-layered approach to quality control significantly enhances confidence in
the library's reliability. The comprehensive QC during the initial construction
phase establishes the baseline accuracy of the resource, confirming correct
integration loci, barcode identities, and low off-target rates. The provision
of dedicated validation primer sets empowers end-users to perform checks on the
specific strains they are working with, mitigating potential issues such as
mislabeling, cross-contamination, or genetic drift over time, thereby
supporting experimental reproducibility.
Furthermore, the
systematic determination of gene essentiality through phenotypic and tetrad
analysis during library construction provides invaluable embedded functional
information. Knowing whether a gene is essential or non-essential is critical
for designing experiments and interpreting results. Essential genes can
typically only be studied effectively in the heterozygous state, while
non-essential genes are available in both formats. This curated essentiality
data, derived directly from the construction process, guides researchers in
selecting appropriate strains and understanding the potential phenotypic
consequences of gene deletion.
4. GPScreen™-FAST: Genome-wide
Screening Service
4.1. Principle: Drug-Induced Haploinsufficiency (DIH)
The GPScreen™-FAST service offered by Bioneer is a functional
genomics platform designed primarily for identifying the cellular targets of
bioactive compounds or drugs. The service operates based on the principle of
Drug-Induced Haploinsufficiency (DIH). This concept posits that if a gene's
product is the direct target of a drug, or is
essential for mediating the drug's effect or mitigating its toxicity, then a
cell with only one functional copy of that gene (i.e., a heterozygous deletion
mutant) will be hypersensitive to the drug compared to a wild-type cell with
two functional copies. The reduced gene dosage in the heterozygote makes the
pathway more vulnerable to inhibition by the drug, leading to a measurable
decrease in growth or fitness at drug concentrations that are only mildly
inhibitory to wild-type cells. This principle specifically necessitates the use
of the comprehensive heterozygous
diploid deletion mutant library, which includes essential genes that cannot be
studied in a haploid state.
4.2. Service Workflow
The GPScreen™-FAST service follows a systematic workflow:
1. Step 1: Primary GI50 Test: Before screening the library, a crucial preliminary step is performed: determining the concentration of the test compound that inhibits the growth of the wild-type S. pombe strain by 50% (GI50). This test, offered as a separate service (3), establishes the appropriate sub-lethal concentration for the main screen. Using the GI50 ensures the concentration is high enough to potentially reveal sensitivities but not so high as to cause overwhelming general toxicity that would mask specific DIH effects.
2. Step 2: Pooled Mutant Screening: The entire pool of heterozygous deletion mutants is cultured simultaneously in liquid medium under two conditions: one containing the test compound at its predetermined GI50 concentration, and a parallel control culture containing the vehicle (e.g., DMSO). The cultures are grown for a defined period, allowing differences in growth rates between strains to manifest.
3. Step 3: Barcode Analysis: Following cultivation, genomic DNA is extracted from both the treated and control pooled populations. The unique UPTAG and DNTAG barcode sequences associated with each mutant strain are then amplified using PCR. These amplified barcode libraries are subjected to Next Generation Sequencing (NGS).
4. Step 4: Data Analysis & Target Identification: The NGS data provides quantitative counts for each unique barcode in both the treated and control samples. By comparing the relative frequency (abundance) of each barcode in the drug-treated sample versus the control sample, strains exhibiting significantly reduced fitness (i.e., lower barcode counts) in the presence of the drug can be identified. These hypersensitive mutants strongly implicate the corresponding deleted gene as being related to the drug's mechanism of action – either as a direct target, a component of the target pathway, or involved in resistance/tolerance mechanisms. The service typically provides an analysis report highlighting these sensitive mutants.
The
integration of pooled library screening, unique molecular barcodes, and
quantitative NGS analysis makes the GPScreen™ service
a powerful, high-throughput method for unbiased, genome-wide drug target
identification. Screening thousands of mutants simultaneously in a pooled
format is vastly more efficient than testing individual strains. The barcodes
enable the accurate deconvolution and quantification of each mutant's relative
abundance within the complex pool after treatment, a task made feasible by the
depth and quantitative nature of NGS.
The initial
determination of the compound's GI50 in wild-type cells is a critical step
influencing the sensitivity and specificity of the DIH screen. The DIH
principle relies on detecting potentially subtle fitness defects in
heterozygous mutants under drug pressure. The GI50 concentration aims to
establish conditions where the drug exerts moderate growth inhibition on the
wild-type population, thereby maximizing the window to detect specific
hypersensitivity in mutants whose deleted gene compromises the drug's target
pathway, without inducing excessive non-specific toxicity that could confound
the results.
4.3. Key Applications
The primary and
most emphasized application of the GPScreen™ service
is drug target identification and
validation. By revealing genes whose heterozygous deletion confers
sensitivity, the screen provides strong candidates for a compound's molecular
targets or pathways.
Beyond primary
target ID, the service is cited for several related applications:
● Mechanism of Action (MoA) Studies: Understanding the broader set of genes affecting sensitivity can illuminate the drug's cellular pathways.
● Drug Toxicity Assessment: Identifying genes involved in mitigating toxicity.
● Drug Repurposing/Repositioning: Screening existing drugs to find new targets or indications.
● Chemical Genomics: Profiling compound interactions across the genome.
● Functional Gene Analysis: Using compounds with known targets to probe gene function.
● Synthetic Lethal Screening: Identifying gene deletions that are lethal only in combination with drug treatment.
● Natural Product Research: Discovering targets and MoA for natural compounds.
Examples
mentioned include identifying PMM1 as a target for terbinafine (an antifungal)
and demonstrating sensitivity to simvastatin (an anti-hyperlipidemic) in the S. pombe system, suggesting advantages
over S. cerevisiae for certain
compound classes.
4.4. Ordering and Deliverables
To utilize the GPScreen™-FAST service, researchers typically follow these
steps:
1. Download the specific order form from the Bioneer website.
2. Complete the form with user information and details about the compound(s) to be screened.
3. Email the completed form to the designated contact address (e.g., gpscreen@bioneer.co.kr).
4. Bioneer reviews the request and provides a quotation based on the scope (e.g., number of compounds).
5. Upon approval of the quotation, the researcher sends a formal purchase order.
6. The researcher ships the compound(s) to Bioneer; the service commences upon receipt.
The
typical deliverables include a detailed report summarizing the experimental
procedure and presenting the analysis results. This report identifies the
mutant strains that exhibited significant sensitivity to the test compound,
ranked based on the change in barcode frequency compared to the control, thus
highlighting the potential gene targets. Raw NGS data may also be provided
depending on the service agreement.
Bioneer also
offers an optional subsequent service for validating the targets identified in S. pombe using RNA interference (siRNA)
in human cells, employing their proprietary SAMiRNA™
technology. While this human cell validation step is complementary, its
detailed discussion falls outside the scope of Bioneer's
S. pombe-specific resources.
5. Accessing S. pombe
Mutant Strains
5.1. Ordering Individual Deletion Mutants
Researchers can
obtain specific, individual deletion mutant strains from Bioneer's
collection, encompassing both heterozygous diploid and haploid (non-essential
gene deletions) formats. The process for ordering these individual strains
involves several steps:
1. Identify Strain Systematic ID: The first step requires the researcher to identify the standard Systematic ID for the gene of interest. This ID must be obtained from the authoritative S. pombe community database, PomBase (https://www.pombase.org/).
2. Place Order on Bioneer Website: The identified Systematic ID is then entered into the search field on the relevant Bioneer product page (e.g., the custom order page for individual strains). The researcher must select the desired mutant type (haploid or diploid) and the preferred shipping format: either cultured on an agar slant (shipped at ambient temperature) or as a glycerol stock (shipped frozen on dry ice, potentially incurring additional costs). Specific catalog numbers may apply, such as M-1010-A for agar type and M-1010-G for glycerol type individual strains.
3. Execute Material Transfer Agreement (MTA): Before Bioneer can ship the strains, a legally binding Material Transfer Agreement (MTA) must be completed and submitted by the researcher's institution. Bioneer provides downloadable MTA templates, offering options for a 5-year license or a Lifetime license. The completed and signed MTA must be emailed to the designated Bioneer address (e.g., sales@bioneer.com).
The
final deliverables are the requested S.
pombe deletion mutant strains, provided as live cultures in the selected
format (agar or glycerol stock).
The reliance on
an external database, PomBase, for strain
identification is noteworthy. While PomBase is the
standard and authoritative resource for S.
pombe genetics, this requirement means users must navigate between the
Bioneer ordering portal and the external database to retrieve the necessary
Systematic ID before placing an order. This integrates Bioneer's
offering with community standards but adds an extra step to the ordering
workflow.
The mandatory
requirement for a signed MTA before shipment underscores the intellectual
property considerations associated with this library. Developed through a
significant academic-industry collaboration, the library likely carries
specific terms of use regarding research applications, publication
acknowledgments, and potential commercial use. The MTA serves as the legal
document outlining these rights and restrictions for the recipient institution,
protecting the developers' contributions and ensuring appropriate use of the
resource.
5.2. Considerations for Other Custom Mutants
It is important
to clarify the scope of "custom orders" in the context of Bioneer's S. pombe
offerings. The primary custom order page focuses specifically on the selection
and ordering of pre-existing deletion
mutant strains from the established library collection.
The provided materials specific to S. pombe do not explicitly advertise or detail services for the de novo generation of other types of
custom S. pombe mutants, such as
those involving specific point mutations, gene knock-ins, epitope tagging, or
promoter replacements using methods like CRISPR-Cas9 or traditional
mutagenesis.
However, Bioneer
does offer general molecular biology services, including gene synthesis and
CRISPR-related services like gRNA design, donor DNA design/synthesis, and
provision of Cas9 components (protein or plasmid). Theoretically, these
capabilities could be applied to generate custom mutations in S. pombe. For instance, the CRISPR
design service explicitly mentions selecting a target organism, implying
potential applicability beyond standard mammalian cells. Similarly, gene
synthesis could be used to create mutated alleles for subsequent integration
into the S. pombe genome.
Despite the
existence of these general capabilities, the lack of dedicated service
packages, protocols, efficiency data, or specific marketing for de novo custom S. pombe mutant generation on the S. pombe-focused web pages suggests this is not a standard, readily
available offering like the deletion strains or the GPScreen™
service. It may indicate either a potential gap in their specialized S. pombe service portfolio or a
strategic marketing decision to primarily promote the high-value deletion
library and associated screening services, which represent a unique resource
stemming from the major collaborative effort.
Therefore,
researchers requiring custom S. pombe
modifications beyond simple gene deletions (e.g., point mutations, knock-ins,
tagging) are advised to contact Bioneer's technical
or sales support directly. Inquiries can be directed to the general sales
contact ([sales@bioneer.com]), the dedicated S. pombe support email ([pombe-support@bioneer.co.kr]), or
potentially the CRISPR service contact ([crispr@bioneer.co.kr]) to discuss
project feasibility, technical approaches, timelines, and obtain a custom
quotation based on Bioneer's underlying gene
synthesis and gene editing capabilities.
6. Conclusion and Recommendations
Summary of Bioneer's S. pombe Platform:
Bioneer provides a robust and valuable platform for S. pombe-based research, centered on a genome-wide deletion mutant library. This resource, encompassing both heterozygous diploid and haploid strains covering ~98.5% of the genome, was developed through a rigorous, internationally collaborative effort and validated according to high scientific standards detailed in peer-reviewed literature. The library's unique barcode design enables powerful high-throughput applications, notably the GPScreen™-FAST service. This service leverages the heterozygous library and the principle of Drug-Induced Haploinsufficiency (DIH) for unbiased, genome-wide drug target identification using NGS-based barcode quantification. Access to individual strains from the collection is facilitated through a clear ordering process, supported by validation tools like specific primer sets.
Recommendations for Researchers:
● For Genome-Wide Drug Target Identification/MoA: The GPScreen™-FAST service, utilizing the heterozygous deletion library, is the recommended approach for unbiased, high-throughput screening of compounds to identify potential molecular targets and elucidate mechanisms of action. Remember to perform the prerequisite GI50 test.
● For Loss-of-Function Studies (Non-Essential Genes): Ordering individual haploid deletion mutants corresponding to the gene(s) of interest is the most direct method for studying phenotypes resulting from complete gene loss.
● For Studying Essential Genes or DIH: Ordering individual heterozygous deletion mutants is necessary for investigating essential genes or for focused studies applying DIH principles to specific gene targets or pathways.
● Ordering Individual Strains: Researchers should utilize the PomBase database (https://www.pombase.org/) to accurately identify the Systematic ID of the desired mutant(s) before ordering. Prompt completion and submission of the required Material Transfer Agreement (MTA) are essential to avoid delays in shipment.
● Quality Control: Upon receiving mutant strains, performing confirmatory QC using colony PCR is advisable. Researchers can utilize Bioneer's AccuOligo® Validation Primer sets or design their own primers based on the known deletion cassette and flanking genomic sequences.
● For Custom Mutations Beyond Deletions: Researchers seeking specific modifications like point mutations, knock-ins, or gene tagging in S. pombe should engage in direct consultation with Bioneer's technical support or sales teams (sales@bioneer.com, gpscreen@bioneer.co.kr). This will allow exploration of the feasibility of leveraging Bioneer's general gene synthesis or CRISPR/gene editing design services for a custom S. pombe engineering project, as dedicated service packages for such modifications are not explicitly listed within their S. pombe product line.
In
conclusion, Bioneer's S. pombe deletion mutant library and associated GPScreen™
service represent a powerful, well-documented resource for the research
community, particularly valuable for functional genomics and drug discovery
efforts leveraging this important eukaryotic model system.